Pulmatrix Targets November Close for Eos Merger as Cash Falls to $1.4M
PULM sits 22% above its 52-week low of $1.06.
Summary
Pulmatrix says its reverse merger with Eos SENOLYTIX should close in November, with Nasdaq listing approval and the approved reverse stock split still outstanding. Stockholders already cleared all nine proposals at the October 26 special meeting, so the remaining items are procedural rather than a vote risk. The balance sheet is the pressure point: Q3 cash and equivalents fell to $1.4M from $4.1M at December 31, 2025, and the company again flagged going-concern uncertainty, with its Q3 loss widening as clinical programs sit paused. Management says cash funds operations at least through the anticipated closing, and $0.7M of restricted cash becomes unrestricted after the merger. For a company this small, the deal is the only clear path to survival — a slip past November leaves little room.
At the time of this announcement, PULM was trading at $1.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9M. The 52-week trading range was $1.06 to $4.98. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.